Profile Picture
  • All
  • Search
  • Images
  • Videos
  • Maps
  • News
  • Copilot
  • More
    • Shopping
    • Flights
    • Travel
  • Notebook
  • Top stories
  • Sports
  • U.S.
  • Local
  • World
  • Science
  • Technology
  • Entertainment
  • Business
  • More
    Politics
Order byBest matchMost fresh
  • Any time
    • Past hour
    • Past 24 hours
    • Past 7 days
    • Past 30 days

Q1, Belite Bio

Digest more
Top News
Overview
Highlights
MarketBeat on MSN · 5h
Belite Bio Q1 earnings call highlights
Key Points Interested in Belite Bio, Inc. Sponsored ADR? Here are five stocks we like better. Belite Bio said it has started a rolling NDA submission to the FDA for Tinlarebant in Stargardt disease and expects to finish by the end of Q2,

Continue reading

 · 6h
Bio-Path: Q1 Earnings Snapshot
 · 16h
Arcos Dorados: Q1 Earnings Snapshot
 · 6h
E.l.f. Beauty: Fiscal Q4 Earnings Snapshot
E.l.f. Beauty Inc. (ELF) on Wednesday reported a loss of $49.4 million in its fiscal fourth quarter.

Continue reading

 · 17h
Lowe's: Fiscal Q1 Earnings Snapshot
 · 17h
Target: Fiscal Q1 Earnings Snapshot
 · 19h
Cadeler: Q1 Earnings Snapshot
On a per-share basis, the Copenhagen V, Denmark-based company said it had a loss of 9 cents.

Continue reading

 · 6h
Star Bulk Carriers: Q1 Earnings Snapshot
 · 6h
Urban Outfitters: Fiscal Q1 Earnings Snapshot
14hon MSN

Annovis Bio slips after pricing $15M equity offering

Annovis Bio (ANVS) shares fell over -7% on Wednesday after the biotechnology company priced an offering to raise approximately $15M. The offering consists of 7,895,000 shares of its common stock and accompanying warrants to purchase up to 7,
CNBC
1y

Bio Rad Laboratories Inc

Bio-Rad Laboratories, Inc. is engaged in developing, manufacturing, and marketing a range of products for the life science research and clinical diagnostics markets. The Company offers a range of products and systems used to separate complex chemical and ...
15h

Passage Bio Inc (PASG) Stock: Should You Buy the Dip For 125% Upside?

Interim data from that trial suggested that PBFT02 may slow disease progression in patients with frontotemporal dementia.
  • Privacy
  • Terms